Rinella, M. E. Et Al. 2025. Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo. JOURNAL OF HEPATOLOGY .

Rinella, M. E., Abdelmalek, M. F., Bugianesi, E., Cali, A., Castera, L., Engebretsen, K. A., ... George, J.(2025). Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo. JOURNAL OF HEPATOLOGY .

Rinella, Mary Et Al. "Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo," JOURNAL OF HEPATOLOGY , 2025

Rinella, Mary E. Et Al. "Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo." JOURNAL OF HEPATOLOGY , 2025

Rinella, M. E. Et Al. (2025) . "Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo." JOURNAL OF HEPATOLOGY .

@article{article, author={Mary E. Rinella Et Al. }, title={Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo}, journal={JOURNAL OF HEPATOLOGY}, year=2025}